Since the introduction of 68Ga-PSMA-11 in 2012 for prostate cancer imaging, tracers targeting prostate-specific membrane antigen (PSMA) have become a focal point in nuclear medicine research [5]. Here, FOLH1 is linked to prostate carcinoma.